Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $8.20

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been given an average recommendation of “Hold” by the seven research firms that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.50.

RGLS has been the subject of a number of recent research reports. Jones Trading reissued a “hold” rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday. Canaccord Genuity Group restated a “hold” rating and set a $11.00 price objective (down from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday. Leerink Partners reiterated a “market perform” rating and issued a $7.00 target price on shares of Regulus Therapeutics in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Friday, March 14th. Finally, Leerink Partnrs downgraded shares of Regulus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $46,000. PEAK6 LLC purchased a new position in shares of Regulus Therapeutics in the 4th quarter valued at $95,000. Oppenheimer & Co. Inc. bought a new position in shares of Regulus Therapeutics in the 1st quarter worth $96,000. Velan Capital Investment Management LP purchased a new stake in shares of Regulus Therapeutics during the 4th quarter worth $111,000. Finally, JPMorgan Chase & Co. boosted its position in Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 52,059 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Stock Performance

RGLS opened at $7.85 on Wednesday. The stock has a market capitalization of $520.01 million, a price-to-earnings ratio of -7.34 and a beta of 1.03. Regulus Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $8.20. The company has a fifty day moving average of $2.11 and a 200 day moving average of $1.66.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, meeting analysts’ consensus estimates of ($0.20). During the same period in the prior year, the business earned ($0.40) EPS. On average, equities research analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.